Results from a study suggest that an intermittent treatment regimen might prevent drug-resistance in patients with melanoma. Vemurafenib-resistant tumours in mice and humans where shown to be dependent on the drug to grow. In 14 out of 19 patients with vemurafenib-resistant tumours, tumour growth decreased after treatment cessation. In animal models, drug resistance was prevented by intermittent dosing. Taken together, these data indicate that intermittent treatment might prevent vemurafenib resistance.
ORIGINAL RESEARCH PAPER
Das Thakur, M. et al. Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance [abstract]. Proc. Ann. Meeting AACR LB-144 (2013)
Rights and permissions
About this article
Cite this article
Intermittent vemurafenib prevents resistance in melanoma. Nat Rev Clin Oncol 10, 250 (2013). https://doi.org/10.1038/nrclinonc.2013.60
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.60